SGD Pharma breaks new ground with a range of premium containers for medicinal food products

SGD Pharma is expanding its offering to include premium products for the Asian markets – with Phoenix, a new range of high-quality glass containers. The range, which is manufactured in China to international standards, offers top cosmetic quality.

With Phoenix, SGD Pharma is targeting the prestigious segment of health products containing “Bird’s Nest”. It is made up of the solidified mucilaginous mucus of swallows, which is rich in collagen and minerals. This luxury seasonal ingredient is mostly consumed in Asia, China, Indonesia, Malaysia, Thailand and Vietnam. SGD Pharma is thus taking account of the importance of Chinese tradition, where medicine and food are closely related.

With Phoenix, SGD Pharma is also addressing industries that commercialise premium food products, such as very high-quality rare honey.

SGD Pharma uses sand with an optimal iron level for enhancing its transparency of the glass products. The glass is therefore clearer and more aesthetically pleasing.

The containers, which are produced in the factory in Zhanjiang (China), meet the international standards and offer a range of possibilities for customised decorations.

See also

SGD Pharma launches industry first ready-to-use sterile 100 ml molded glass vials in SG EZ-fill packaging technology

Worldwide glass primary packaging supplier SGD Pharma has announced the introduction of its 100H ml Ready-to-Use (RTU) Type I molded glass vials for aseptic fill/finish of parenteral drug products. The addition of 100 ml molded glass vials to the Sterinity platform is pioneering, with SGD Pharma being the first global molded glass manufacturing company to offer this size of solution in the RTU market.

SGD Pharma speeds up time to market with industry first Ready-to-Use Nest & Tub packaging solution for molded glass vials

Increased demand for parenteral drugs generated by the Covid-19 pandemic has resulted in additional pressures being placed on biopharmaceutical companies to accelerate their time-to-market. This new RTU primary and secondary packaging combination from SGD Pharma offers biopharmaceutical producers the flexibility they need to deliver innovative medicines to patients significantly faster.

SGD Pharma upgrades its Chinese plant toward an automated and improved production

SGD Pharma's Zhanjiang (China) plant produces 1.2 million Type II & III flint molded glass vials daily for the parenteral market and for health care beauty products. With a surface of ​​85,000m2, the plant included a glass furnace, 6 production lines, an ISO 8 clean room of 2000m2, a resorting room and a customization workshop. In early 2018, SGD Pharma invested 7 million Euros to improve the automation and the production, including the rebuilding of the furnace, to make the plant an exemplary production center.

  • Jo Webb
  • Product Info
  • English
  • Created 01 Oct 2018
  • Modified 24 Oct 2018
  • Hits 714